District Court Finds PK Targets Of VIMOVO Patents Indefinite

27 November 2018 PharmaPatents Blog
Authors: Courtenay C. Brinckerhoff

In an opinion issued November 19, 2018, Judge Chesler of the U.S. District Court for the District of New Jersey found two Orange Book-listed patents for VIMOVO® invalid for indefiniteness in the way certain pharmacokinetic (PK) properties were recited. The opinion supports the court’s summary judgement of invalidity of the patents.

The VIMOVO® Patents At Issue

The VIMOV® patents at issue in this decision were U.S. Patent Nos. 9,220,698 and 9,393,208, which claim methods of treating, e.g., osteoarthritis or rheumatoid arthritis, by administering “AM” and “PM” unit dose forms comprising naproxen and esomeprazole, wherein the AM and PM unit dose forms “target” certain pharmacokinetic profiles, such as certain Cmax, Tmax, and mean plasma concentration AUC levels.

Indefiniteness Of “Target” PK Values

The court first considered whether the “target” clauses were limiting or merely recited intended results of the claimed methods. On this issue, the court determined that the Applicant’s reliance on these features during examination to distinguish prior art required that they be given weight.

Turning to the indefiniteness issue, the court applied its construction of the term “target” as meaning “set as a goal,” and found the claims indefinite. Indeed, reading the opinion begs the question whether that claim construction doomed the claims from the outset.

The court reasoned:

The fundamental difficulty is that both key phrases here are incomprehensible: “the AM and PM unit dose forms target:” and “the AM and PM unit dose forms further target.” It is not possible to comprehend what these phrases mean, because pills cannot be said to set goals. In ordinary usage, we understand a goal to be something that people, or perhaps living creatures, set; inanimate objects set no goals.

According to Judge Chesler, because target” was construed to mean “set as a goal,” and because the claims recite that the dosage forms “target” the recited PK parameters, the claims are “incomprehensible” because dosage forms cannot set goals.

Even putting that particular conundrum aside, the court noted, “The problem here is that the target clauses fail to draw clear boundaries.” That is, the court could “see[] no way that defining the goals for a method can, without more, inform the public of how to act to avoid infringement.”

The court found that the Patentee’s arguments treated “target” as meaning “produce,” which was inconsistent with the claim construction and therefore unhelpful (or, in the court’s words, “defective”).

Thus, the court concluded that the claims, “read in light of the specification delineating the patents, and the prosecution history, fail to inform, with reasonable certainty, those skilled in the art about the scope of the invention,” and therefore are invalid as indefinite.

Why “Target” PK Values?

The “target” language at issue in this case is found in the original claims, and appears throughout the patent specifications without express definition or direct explanation. It is possible that this terminology was chosen with the knowledge that not every administration of the claimed AM and PM dose units would achieve the recited PK parameters in every patient. Unfortunately for the Patentees here, the court rejected their argument that “target” should be construed as “produce,” which also foreclosed their arguments that the recited PK parameters were average values obtained across a group of patients.

In parallel Inter Partes Review proceedings, the USPTO Patent Trial and Appeal Board constructed “target” as “have or set the goal of obtaining.” Would the “have” aspect of that construction left room for a different result here?

This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.